ProQR Therapeutics N.V. (NasdaqCM: PRQR)
Health Care · Biotechnology · NL
$2.35
+0.43% today · +4.0% 1Y
ProQR Therapeutics N.V. (NasdaqCM: PRQR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $330.22M and employs 166 people.
Over the last twelve months the share price has gained 4.0%, trading between 1.33 and 3.10.
Tweenvest scores ProQR Therapeutics N.V. across four factors: quality 38/100, value 62/100. Its strongest factor is value.
PRQR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $330.22M
- Revenue (TTM)
- $21.05M
- P/E
- —
- EPS
- -0.40
- Dividend yield
- —
- Beta (5Y)
- 0.03
- 52-week high
- $3.10
- 52-week low
- $1.33
- Avg volume (3M)
- —
- Shares outstanding
- 141.12M
- Employees
- 166
- Next earnings
- —
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
- ISIN
- NL0010872495
- Founded
- 2012
- Listed since
- Sep 18, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.